Navigation Links
Johnson & Johnson Honors 2009 Recipient of The Dr. Paul Janssen Award for Biomedical Research
Date:9/8/2009

nssen Award salutes the most passionate and creative scientists in basic or clinical research whose scientific achievements have made, or have strong potential to make, a measurable impact on human health. The Dr. Paul Janssen Award is named for Dr. Paul Janssen, who founded Janssen Pharmaceutica, N.V. in 1953. Known to his colleagues as "Dr. Paul," Janssen was one of the 20th century's most gifted and passionate researchers, a physician-scientist who helped save millions of lives through his contribution to the discovery and development of more than 80 medicines, of which four are on the World Health Organization's list of essential medicines. In 1961, Janssen Pharmaceutica, N.V. joined the Johnson & Johnson Family of Companies. Janssen's legacy continues to inspire Johnson & Johnson and its commitment to finding innovative cures for unmet medical needs. Nominations for the 2010 Dr. Paul Janssen Award will open later this fall and submission details will be available at www.pauljanssenaward.com.

About the Selection Committee

The Dr. Paul Janssen Award independent Selection Committee is composed of some of the world's leading scientists, including National Medal of Science winners, Nobel Laureates, members of the National Academy of Sciences and past winners of The Dr. Paul Janssen Award. The 2009 Selection Committee includes:

  • Solomon Snyder, M.D., (chairman) distinguished service professor of Neuroscience, Pharmacology and Psychiatry, Johns Hopkins School of Medicine; co-winner, 1978 Albert Lasker Award; winner, 2003 National Medal of Science (United States)
  • Mary-Claire King, Ph.D., American Cancer Society Professor of Medicine and Genome Sciences, University of Washington, Seattle; member, National Academy of Sciences; member, American Academy of Arts and Sciences (United States)
  • J
    '/>"/>

SOURCE Johnson & Johnson
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cempra Pharmaceuticals Announces Appointment of John H. Johnson to Board of Directors
2. Johnson & Johnson Completes Acquisition of Cougar Biotechnology
3. Johnson & Johnson Completes Initial Tender Offer for Cougar Biotechnology
4. Johnson & Johnson Announces Regulatory Clearance for Its Planned Acquisition of Cougar Biotechnology
5. Johnson & Johnson Begins Tender Offer to Acquire Cougar Biotechnology
6. Johnson & Johnson Announces Definitive Agreement to Acquire Cougar Biotechnology, Inc.
7. Simbionix and Johnson & Johnson LLC Announce a Distribution Agreement for Russia and the CIS Countries
8. Burnham Announces Assay Development and License Agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
9. Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.
10. Johnson & Johnson Announces Definitive Agreement to Acquire Omrix
11. Cynvec LLC(SM) Appoints Former Johnson & Johnson Executive Frank D. Stonebanks as President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... THOUSAND OAKS, Calif. , July 25, 2014 /PRNewswire/ ... its Board of Directors today declared a $0.61 per ... dividend will be paid on Sept. 5, 2014, to ... business on Aug. 14, 2014.  About ... biology for patients suffering from serious illnesses by discovering, ...
(Date:7/25/2014)... 2014 WABC Radio show out of New ... Lorry Young will be hosting California-based Vet-Stem, Inc.’s Founder and ... therapy in pets. Dr. Harman first visited the show ... therapy for pets suffering from osteoarthritis and other degenerative diseases, ... industry forward. , Young has invited Dr. Harman back to ...
(Date:7/25/2014)... At the request of the AMA, ... extension for the public comment period (Docket No. FAA-2014-0396) ... Aircraft established by Congress as part of the FAA ... establishes the new deadline for comments as September 23, ... notice published in the Federal Register on July 25, ...
(Date:7/24/2014)... Calif. , July 24, 2014  Now available ... to home. Rehealth Regenerative Therapies , located in ... and other physically active people a new health option: ... Regardless of age, countless patients suffer from joint ... activities, such as muscle tears, torn rotator cuff, tennis ...
Breaking Biology Technology:Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 3FAA Grants Comment Extension at the Request of AMA 2Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3
... Jan. 12 Synvista Therapeutics, Inc. (NYSE Alternext ... its BENEFICIAL study, a Phase 2 double-blind, placebo-controlled, randomized trial ... measure the effect of alagebrium on exercise tolerance in patients ... completing enrollment of its BREAK ( B eginning a ...
... Ill. and SANTA ANA, Calif., Jan. 12 ,Abbott ( NYSE: ... EYE ) announced,today a definitive agreement for Abbott to acquire ... value of approximately $2.8 billion, inclusive,of estimated net debt at ... AMO,is a global leader in ophthalmic care, comprised of three ...
... Bavarian Nordic,owns several United States patents relating ... MVA-BN(R), which is the basis for its smallpox,vaccine, ... for delivering,recombinant vaccines. Bavarian Nordic has asserted three ... The claim in this case is that Oxford,BioMedica ...
Cached Biology Technology:Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium 2Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium 3Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium 4Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 2Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 3Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 4Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 5Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 6Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 7Bavarian Nordic's Case Against Oxford BioMedica 2
(Date:7/25/2014)... Spina bifda (SB) is a complex congenital central ... incomplete closing of the neural tubes during the ... spasticity, urinary and fecal incontinence and neurocognitive retardation. ... their quality of life. Researchers at Ankara Physical ... investigate the functional performance in children with SB, ...
(Date:7/25/2014)... The routine use of a molecular testing panel ... performing the correct initial surgery for patients with ... University of Pittsburgh Cancer Institute (UPCI), partner with ... Multidisciplinary Thyroid Center and other diagnostic testing agencies, ... initial surgery by 30 percent, according to the ...
(Date:7/24/2014)... of how wildlife loss leads to conflict among people ... Wildlife Conservation Society (WCS) Health & Ecosystems: Analysis of ... an interdisciplinary approach to tackle global biodiversity decline. , ... of the world,s people and provides protein for more ... come as no surprise that today,s unprecedented loss of ...
Breaking Biology News(10 mins):Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3New study draws links between wildlife loss and social conflicts 2
... are succumbing to infection with canine distemper virus (CDV), a ... authors of a study published in mBio , the ... Pressure from poaching, decimation of their prey base, and ... called Siberian tigers) to fewer than 500. In the study, ...
... clinicians have an interest in how the cells of our ... to grow, to heal, to transmit information internally, to mount ... necessary for survival. But if cell mobility is unregulated, tumors ... multi-disciplinary study by University of Pennsylvania researchers has now illuminated ...
... 2013  Local Pearle Vision licensee, Theresa Ayers , has added ... with her husband, Ronald Ayers , the husband-and-wife team assumed ... Everhard Road N.W. Theresa Ayers has been with Pearle Vision, one ... licensed optical brands, for more than three decades. She began her ...
Cached Biology News:Canine distemper virus: An emerging disease in rare Amur tigers 2Multi-disciplinary Penn research identifies protein required for cell movement 2Multi-disciplinary Penn research identifies protein required for cell movement 3Local Pearle Vision Licensee Adds Second Center In Canton, Ohio 2Local Pearle Vision Licensee Adds Second Center In Canton, Ohio 3Local Pearle Vision Licensee Adds Second Center In Canton, Ohio 4Local Pearle Vision Licensee Adds Second Center In Canton, Ohio 5
... GyroTwister GX-1000 3-D Shaker , ... shaking motion of the GyroTwister GX-1000 is ... ideal for general mixing as well as ... speed is continuously adjustable across a broad ...
...
... Radiochemical Purity is >95%NEN Radiolabeled Ligands\n\nReceptor-related ... continual availability of new radiolabeled ligands selected ... offers a wide range of products and ... including over 400 state-of-the-art radioligands. If you ...
...
Biology Products: